Neurotrauma 33 , 18481854 (2016)
It catalyses a reaction which converts 4-trimethylammoniobutanoate (-butyrobetaine) into L-carnitine.: [10] [11] The enzyme is a non-heme iron protein with ferryl active site where Fe(IV)=O is the species that transfers its oxygen to the substrate
Conclusion BPC-157 represents an intriguing case study in modern biohacking and longevity culture: a compound with a compelling origin story, hundreds of preclinical studies, plausible biological mechanisms, and virtually no clinical evidence of human efficacy or safety
Furthermore, formulations demonstrating greater bioavailability based on blood levels have not always shown greater clinical benefit
Our products include prescription solutions, lyophilized injections, critical care medicines, lifesaving drugs, anti-cancer drugs, veterinary products, consumer brands, and CNS drugs
There are currently 7 published articles from this trial, with a further 8 either unpublished or recruiting volunteers